Pdb68 - Cost-Effectiveness Analysis of Exenatide Versus GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.773
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes on Oral Antidiabetic Drugs in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Selecting GLP-1 Agonists in the Management of Type 2 Diabetes: Differential Pharmacology and Therapeutic Benefits of Liraglutide and Exenatide

Therapeutics and Clinical Risk Management
2010English

Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-On Therapy in Chinese Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Efficacy and Safety of Exenatide Versus Insulin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

International Journal of Management, Economics and Social Sciences
2019English

Pdb110 - Treatment Persistence in Patients With Type 2 Diabetes Treated With GLP-1 Receptor Agonists in Clinical Practice in Sweden: Nationwide Retrospective Cohort Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Evaluating Preferences for Profiles of GLP-1 Receptor Agonists Among Injection-Naïve Type 2 Diabetes Patients in the UK

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2015English

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Pdb112 - Treatment and Dosing Patterns Among Patients With Type 2 Diabetes (T2d) Initiating Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 Ras) in Several Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy